Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTAPLO1S)

• DOT Name: Epidermal growth factor receptor (EGFR)
• Synonyms: EC 2.7.10.1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
• Gene Name: EGFR
• Related Disease:
  Lung cancer
  Non-small-cell lung cancer
  Inflammatory skin and bowel disease, neonatal, 2
  Neonatal inflammatory skin and bowel disease
• UniProt ID: EGFR_HUMAN
• PDB ID: 1IVO ; 1M14 ; 1M17 ; 1MOX ; 1NQL ; 1XKK ; 1YY9 ; 1Z9I ; 2EB2 ; 2EB3 ; 2GS2 ; 2GS6 ; 2GS7 ; 2ITN ; 2ITO ; 2ITP ; 2ITQ ; 2ITT ; 2ITU ; 2ITV ; 2ITW ; 2ITX ; 2ITY ; 2ITZ ; 2J5E ; 2J5F ; 2J6M ; 2JIT ; 2JIU ; 2JIV ; 2KS1 ; 2M0B ; 2M20 ; 2N5S ; 2RF9 ; 2RFD ; 2RFE ; 2RGP ; 3B2U ; 3B2V ; 3BEL ; 3BUO ; 3C09 ; 3G5V ; 3G5Y ; 3GOP ; 3GT8 ; 3IKA ; 3LZB ; 3NJP ; 3OB2 ; 3OP0 ; 3P0Y ; 3PFV ; 3POZ ; 3QWQ ; 3UG1 ; 3UG2 ; 3VJN ; 3VJO ; 3VRP ; 3VRR ; 3W2O ; 3W2P ; 3W2Q ; 3W2R ; 3W2S ; 3W32 ; 3W33 ; 4G5J ; 4G5P ; 4HJO ; 4I1Z ; 4I20 ; 4I21 ; 4I22 ; 4I23 ; 4I24 ; 4JQ7 ; 4JQ8 ; 4JR3 ; 4JRV ; 4KRL ; 4KRM ; 4KRO ; 4KRP ; 4LI5 ; 4LL0 ; 4LQM ; 4LRM ; 4R3P ; 4R3R ; 4R5S ; 4RIW ; 4RIX ; 4RIY ; 4RJ4 ; 4RJ5 ; 4RJ6 ; 4RJ7 ; 4RJ8 ; 4TKS ; 4UIP ; 4UV7 ; 4WD5 ; 4WKQ ; 4WRG ; 4ZAU ; 4ZJV ; 4ZSE ; 5C8K ; 5C8M ; 5C8N ; 5CAL ; 5CAN ; 5CAO ; 5CAP ; 5CAQ ; 5CAS ; 5CAU ; 5CAV ; 5CNN ; 5CNO ; 5CZH ; 5CZI ; 5D41 ; 5EDP ; 5EDQ ; 5EDR ; 5EM5 ; 5EM6 ; 5EM7 ; 5EM8 ; 5FED ; 5FEE ; 5FEQ ; 5GMP ; 5GNK ; 5GTY ; 5GTZ ; 5HCX ; 5HCY ; 5HCZ ; 5HG5 ; 5HG7 ; 5HG8 ; 5HG9 ; 5HIB ; 5HIC ; 5J9Y ; 5J9Z ; 5JEB ; 5LV6 ; 5SX4 ; 5SX5 ; 5U8L ; 5UG8 ; 5UG9 ; 5UGA ; 5UGB ; 5UGC ; 5UWD ; 5WB7 ; 5WB8 ; 5X26 ; 5X27 ; 5X28 ; 5X2A ; 5X2C ; 5X2F ; 5X2K ; 5XDK ; 5XDL ; 5XGM ; 5XGN ; 5XWD ; 5Y25 ; 5Y9T ; 5YU9 ; 5ZTO ; 5ZWJ ; 6ARU ; 6B3S ; 6D8E ; 6DUK ; 6JRJ ; 6JRK ; 6JRX ; 6JWL ; 6JX0 ; 6JX4 ; 6JXT ; 6JZ0 ; 6LUB ; 6LUD ; 6P1D ; 6P1L ; 6P8Q ; 6S89 ; 6S8A ; 6S9B ; 6S9C ; 6S9D ; 6TFU ; 6TFV ; 6TFW ; 6TFY ; 6TFZ ; 6TG0 ; 6TG1 ; 6V5N ; 6V5P ; 6V66 ; 6V6K ; 6V6O ; 6VH4 ; 6VHN ; 6VHP ; 6WA2 ; 6WAK ; 6WXN ; 6XL4 ; 6Z4B ; 6Z4D ; 7A2A ; 7A6I ; 7A6J ; 7A6K ; 7AEI ; 7AEM ; 7B85 ; 7ER2 ; 7JXI ; 7JXK ; 7JXL ; 7JXM ; 7JXP ; 7JXQ ; 7JXW ; 7K1H ; 7K1I ; 7KXZ ; 7KY0 ; 7LEN ; 7LFR ; 7LFS ; 7LG8 ; 7LGS ; 7LTX ; 7OM4 ; 7OXB ; 7SI1 ; 7SYD ; 7SYE ; 7SZ0 ; 7SZ1 ; 7SZ5 ; 7SZ7 ; 7T4I ; 7T4J ; 7TVD ; 7U98 ; 7U99 ; 7U9A ; 7UKV ; 7UKW ; 7VRA ; 7VRE ; 7ZYM ; 7ZYN ; 7ZYP ; 7ZYQ ; 8A27 ; 8A2A ; 8A2B ; 8A2D ; 8D73 ; 8D76 ; 8DSW ; 8EME ; 8F1H ; 8F1W ; 8F1X ; 8F1Y ; 8F1Z ; 8G63 ; 8H7X ; 8HGO ; 8HGP ; 8HGS ; 8HY7
• EC Number: 2.7.10.1
• Pfam ID: PF00757 ; PF14843 ; PF07714 ; PF01030 ; PF21314
• Sequence:
  MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV
  VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA
  VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF
  QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC
  TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV
  VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK
  NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF
  ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL
  FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN
  LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
  GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV
  ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS
  GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI
  CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA
  RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY
  GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK
  FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ
  QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED
  SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN
  TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV
  APQSSEFIGA
• Function: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration. Plays a role in enhancing learning and memory performance. Plays a role in mammalian pain signaling (long-lasting hypersensitivity); Isoform 2 may act as an antagonist of EGF action.; (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.
• Tissue Specificity: Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.
• KEGG Pathway:
  EGFR tyrosine ki.se inhibitor resistance (hsa01521)
  Endocrine resistance (hsa01522)
  MAPK sig.ling pathway (hsa04010)
  ErbB sig.ling pathway (hsa04012)
  Ras sig.ling pathway (hsa04014)
  Rap1 sig.ling pathway (hsa04015)
  Calcium sig.ling pathway (hsa04020)
  HIF-1 sig.ling pathway (hsa04066)
  FoxO sig.ling pathway (hsa04068)
  Phospholipase D sig.ling pathway (hsa04072)
  Endocytosis (hsa04144)
  PI3K-Akt sig.ling pathway (hsa04151)
  Focal adhesion (hsa04510)
  Adherens junction (hsa04520)
  Gap junction (hsa04540)
  JAK-STAT sig.ling pathway (hsa04630)
  Regulation of actin cytoskeleton (hsa04810)
  GnRH sig.ling pathway (hsa04912)
  Estrogen sig.ling pathway (hsa04915)
  Oxytocin sig.ling pathway (hsa04921)
  Relaxin sig.ling pathway (hsa04926)
  Parathyroid hormone synthesis, secretion and action (hsa04928)
  Cushing syndrome (hsa04934)
  Epithelial cell sig.ling in Helicobacter pylori infection (hsa05120)
  Shigellosis (hsa05131)
  Hepatitis C (hsa05160)
  Human cytomegalovirus infection (hsa05163)
  Human papillomavirus infection (hsa05165)
  Coro.virus disease - COVID-19 (hsa05171)
  Pathways in cancer (hsa05200)
  Proteoglycans in cancer (hsa05205)
  MicroR.s in cancer (hsa05206)
  Chemical carcinogenesis - receptor activation (hsa05207)
  Chemical carcinogenesis - reactive oxygen species (hsa05208)
  Colorectal cancer (hsa05210)
  Pancreatic cancer (hsa05212)
  Endometrial cancer (hsa05213)
  Glioma (hsa05214)
  Prostate cancer (hsa05215)
  Melanoma (hsa05218)
  Bladder cancer (hsa05219)
  Non-small cell lung cancer (hsa05223)
  Breast cancer (hsa05224)
  Hepatocellular carcinoma (hsa05225)
  Gastric cancer (hsa05226)
  Central carbon metabolism in cancer (hsa05230)
  Choline metabolism in cancer (hsa05231)
  PD-L1 expression and PD-1 checkpoint pathway in cancer (hsa05235)
• Reactome Pathway:
  Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants (R-HSA-1236382)
  Signaling by ERBB4 (R-HSA-1236394)
  SHC1 events in ERBB2 signaling (R-HSA-1250196)
  PLCG1 events in ERBB2 signaling (R-HSA-1251932)
  PIP3 activates AKT signaling (R-HSA-1257604)
  Signaling by EGFR (R-HSA-177929)
  GRB2 events in EGFR signaling (R-HSA-179812)
  GAB1 signalosome (R-HSA-180292)
  SHC1 events in EGFR signaling (R-HSA-180336)
  EGFR downregulation (R-HSA-182971)
  GRB2 events in ERBB2 signaling (R-HSA-1963640)
  PI3K events in ERBB2 signaling (R-HSA-1963642)
  EGFR interacts with phospholipase C-gamma (R-HSA-212718)
  EGFR Transactivation by Gastrin (R-HSA-2179392)
  Constitutive Signaling by Aberrant PI3K in Cancer (R-HSA-2219530)
  Signal transduction by L1 (R-HSA-445144)
  Constitutive Signaling by EGFRvIII (R-HSA-5637810)
  Inhibition of Signaling by Overexpressed EGFR (R-HSA-5638303)
  RAF/MAP kinase cascade (R-HSA-5673001)
  ERBB2 Regulates Cell Motility (R-HSA-6785631)
  PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling (R-HSA-6811558)
  ERBB2 Activates PTK6 Signaling (R-HSA-8847993)
  Cargo recognition for clathrin-mediated endocytosis (R-HSA-8856825)
  Clathrin-mediated endocytosis (R-HSA-8856828)
  PTK6 promotes HIF1A stabilization (R-HSA-8857538)
  Downregulation of ERBB2 signaling (R-HSA-8863795)
  TFAP2 (AP-2) family regulates transcription of growth factors and their receptors (R-HSA-8866910)
  Extra-nuclear estrogen signaling (R-HSA-9009391)
  NOTCH3 Activation and Transmission of Signal to the Nucleus (R-HSA-9013507)
  HCMV Early Events (R-HSA-9609690)
  Estrogen-dependent nuclear events downstream of ESR-membrane signaling (R-HSA-9634638)
  Signaling by ERBB2 KD Mutants (R-HSA-9664565)
  Signaling by ERBB2 ECD mutants (R-HSA-9665348)
  Signaling by ERBB2 TMD/JMD mutants (R-HSA-9665686)
  Signaling by ERBB2 (R-HSA-1227986)

Molecular Interaction Atlas (MIA) of This DOT

4 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Lung cancer	DISCM4YA	Definitive	Autosomal dominant	[1]
Non-small-cell lung cancer	DIS5Y6R9	Definitive	Autosomal dominant	[2]
Inflammatory skin and bowel disease, neonatal, 2	DIS1RP9A	Strong	Autosomal recessive	[3]
Neonatal inflammatory skin and bowel disease	DISMIIM2	Supportive	Autosomal recessive	[3]

This DOT Affected the Drug Response of 15 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Cisplatin	DMRHGI9	Approved	Epidermal growth factor receptor (EGFR) decreases the response to substance of Cisplatin.	[89]
Fluorouracil	DMUM7HZ	Approved	Epidermal growth factor receptor (EGFR) decreases the response to substance of Fluorouracil.	[90]
Dasatinib	DMJV2EK	Approved	Epidermal growth factor receptor (EGFR) increases the response to substance of Dasatinib.	[91]
Gefitinib	DM15F0X	Approved	Epidermal growth factor receptor (EGFR) decreases the response to substance of Gefitinib.	[91]
Docetaxel	DMDI269	Approved	Epidermal growth factor receptor (EGFR) decreases the response to substance of Docetaxel.	[92]
Crizotinib	DM4F29C	Approved	Epidermal growth factor receptor (EGFR) decreases the response to substance of Crizotinib.	[94]
Triamterene	DM2HU9I	Approved	Epidermal growth factor receptor (EGFR) affects the response to substance of Triamterene.	[95]
L-glutamine	DM69G8X	Approved	Epidermal growth factor receptor (EGFR) increases the Cytogenetic investigations ADR of L-glutamine.	[96]
Cetuximab	DMLNCE0	Approved	Epidermal growth factor receptor (EGFR) increases the Neoplasm related morbidities ADR of Cetuximab.	[96]
Erlotinib	DMCMBHA	Approved	Epidermal growth factor receptor (EGFR) increases the response of Erlotinib.	[97]
Afimoxifene	DMFORDT	Phase 2	Epidermal growth factor receptor (EGFR) decreases the response to substance of Afimoxifene.	[98]
GDC0941	DM1YAK6	Phase 2	Epidermal growth factor receptor (EGFR) increases the response to substance of GDC0941.	[99]
GDC-0980/RG7422	DMF3MV1	Phase 2	Epidermal growth factor receptor (EGFR) increases the response to substance of GDC-0980/RG7422.	[99]
Ribavirin	DMEYLH9	Phase 1 Trial	Epidermal growth factor receptor (EGFR) increases the Hepatic function abnormal ADR of Ribavirin.	[96]
NVP-TAE684	DMFZXI2	Investigative	Epidermal growth factor receptor (EGFR) decreases the response to substance of NVP-TAE684.	[100]

This DOT Affected the Regulation of Drug Effects of 1 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
2-deoxyglucose	DMIAHVU	Approved	Epidermal growth factor receptor (EGFR) increases the import of 2-deoxyglucose.	[93]

22 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate decreases the methylation of Epidermal growth factor receptor (EGFR).	[4]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate increases the phosphorylation of Epidermal growth factor receptor (EGFR).	[9]
Vorinostat	DMWMPD4	Approved	Vorinostat decreases the phosphorylation of Epidermal growth factor receptor (EGFR).	[17]
Rosiglitazone	DMILWZR	Approved	Rosiglitazone increases the phosphorylation of Epidermal growth factor receptor (EGFR).	[24]
Nicotine	DMWX5CO	Approved	Nicotine increases the phosphorylation of Epidermal growth factor receptor (EGFR).	[28]
Acocantherin	DM7JT24	Approved	Acocantherin decreases the phosphorylation of Epidermal growth factor receptor (EGFR).	[34]
Adenosine triphosphate	DM79F6G	Approved	Adenosine triphosphate increases the phosphorylation of Epidermal growth factor receptor (EGFR).	[40]
Carvedilol	DMHTEAO	Approved	Carvedilol increases the phosphorylation of Epidermal growth factor receptor (EGFR).	[47]
Sotorasib	DMLSV74	Approved	Sotorasib increases the phosphorylation of Epidermal growth factor receptor (EGFR).	[51]
Amiodarone	DMUTEX3	Phase 2/3 Trial	Amiodarone decreases the phosphorylation of Epidermal growth factor receptor (EGFR).	[62]
BAICALEIN	DM4C7E6	Phase 2	BAICALEIN decreases the phosphorylation of Epidermal growth factor receptor (EGFR).	[67]
Delphinidin	DMS2WIN	Phase 2	Delphinidin decreases the phosphorylation of Epidermal growth factor receptor (EGFR).	[69]
Ym155	DM5Q1W4	Phase 2	Ym155 decreases the phosphorylation of Epidermal growth factor receptor (EGFR).	[71]
G1	DMTV42K	Phase 1/2	G1 increases the phosphorylation of Epidermal growth factor receptor (EGFR).	[72]
Taurocholic acid	DM2LZ8F	Phase 1/2	Taurocholic acid increases the phosphorylation of Epidermal growth factor receptor (EGFR).	[73]
Tetrandrine	DMAOJBX	Phase 1	Tetrandrine decreases the phosphorylation of Epidermal growth factor receptor (EGFR).	[76]
BETULINIC ACID	DMBUI2A	Phase 1	BETULINIC ACID increases the phosphorylation of Epidermal growth factor receptor (EGFR).	[77]
Sphingosine-1-Phosphate	DMJCQKA	Phase 1	Sphingosine-1-Phosphate increases the phosphorylation of Epidermal growth factor receptor (EGFR).	[73]
Terfenadine	DM4KLPT	Withdrawn from market	Terfenadine decreases the phosphorylation of Epidermal growth factor receptor (EGFR).	[84]
Alprenolol	DMYJ8Z3	Withdrawn from market	Alprenolol increases the phosphorylation of Epidermal growth factor receptor (EGFR).	[47]
Acteoside	DM0YHKB	Terminated	Acteoside decreases the phosphorylation of Epidermal growth factor receptor (EGFR).	[87]
WIN-55212-2	DMACBIW	Terminated	WIN-55212-2 increases the phosphorylation of Epidermal growth factor receptor (EGFR).	[88]

77 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Ciclosporin	DMAZJFX	Approved	Ciclosporin increases the expression of Epidermal growth factor receptor (EGFR).	[5]
Tretinoin	DM49DUI	Approved	Tretinoin decreases the expression of Epidermal growth factor receptor (EGFR).	[6]
Acetaminophen	DMUIE76	Approved	Acetaminophen decreases the expression of Epidermal growth factor receptor (EGFR).	[7]
Doxorubicin	DMVP5YE	Approved	Doxorubicin decreases the expression of Epidermal growth factor receptor (EGFR).	[8]
Estradiol	DMUNTE3	Approved	Estradiol decreases the expression of Epidermal growth factor receptor (EGFR).	[10]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Epidermal growth factor receptor (EGFR).	[11]
Arsenic	DMTL2Y1	Approved	Arsenic decreases the expression of Epidermal growth factor receptor (EGFR).	[12]
Quercetin	DM3NC4M	Approved	Quercetin decreases the expression of Epidermal growth factor receptor (EGFR).	[13]
Arsenic trioxide	DM61TA4	Approved	Arsenic trioxide decreases the expression of Epidermal growth factor receptor (EGFR).	[14]
Hydrogen peroxide	DM1NG5W	Approved	Hydrogen peroxide affects the expression of Epidermal growth factor receptor (EGFR).	[15]
Calcitriol	DM8ZVJ7	Approved	Calcitriol increases the expression of Epidermal growth factor receptor (EGFR).	[16]
Testosterone	DM7HUNW	Approved	Testosterone increases the expression of Epidermal growth factor receptor (EGFR).	[16]
Decitabine	DMQL8XJ	Approved	Decitabine increases the expression of Epidermal growth factor receptor (EGFR).	[18]
Marinol	DM70IK5	Approved	Marinol increases the expression of Epidermal growth factor receptor (EGFR).	[19]
Selenium	DM25CGV	Approved	Selenium decreases the expression of Epidermal growth factor receptor (EGFR).	[20]
Progesterone	DMUY35B	Approved	Progesterone increases the expression of Epidermal growth factor receptor (EGFR).	[21]
Niclosamide	DMJAGXQ	Approved	Niclosamide decreases the expression of Epidermal growth factor receptor (EGFR).	[22]
Isotretinoin	DM4QTBN	Approved	Isotretinoin decreases the expression of Epidermal growth factor receptor (EGFR).	[6]
Troglitazone	DM3VFPD	Approved	Troglitazone decreases the expression of Epidermal growth factor receptor (EGFR).	[23]
Aspirin	DM672AH	Approved	Aspirin increases the expression of Epidermal growth factor receptor (EGFR).	[25]
Etoposide	DMNH3PG	Approved	Etoposide decreases the expression of Epidermal growth factor receptor (EGFR).	[26]
Paclitaxel	DMLB81S	Approved	Paclitaxel decreases the expression of Epidermal growth factor receptor (EGFR).	[27]
Piroxicam	DMTK234	Approved	Piroxicam decreases the expression of Epidermal growth factor receptor (EGFR).	[29]
Cocaine	DMSOX7I	Approved	Cocaine decreases the expression of Epidermal growth factor receptor (EGFR).	[30]
Topotecan	DMP6G8T	Approved	Topotecan decreases the expression of Epidermal growth factor receptor (EGFR).	[31]
Gemcitabine	DMSE3I7	Approved	Gemcitabine decreases the expression of Epidermal growth factor receptor (EGFR).	[32]
Capsaicin	DMGMF6V	Approved	Capsaicin decreases the expression of Epidermal growth factor receptor (EGFR).	[33]
Alitretinoin	DMME8LH	Approved	Alitretinoin decreases the expression of Epidermal growth factor receptor (EGFR).	[6]
Vitamin C	DMXJ7O8	Approved	Vitamin C decreases the expression of Epidermal growth factor receptor (EGFR).	[35]
Sorafenib	DMS8IFC	Approved	Sorafenib decreases the expression of Epidermal growth factor receptor (EGFR).	[36]
Sertraline	DM0FB1J	Approved	Sertraline increases the expression of Epidermal growth factor receptor (EGFR).	[37]
Dinoprostone	DMTYOPD	Approved	Dinoprostone increases the expression of Epidermal growth factor receptor (EGFR).	[38]
Ardeparin	DMYRX8B	Approved	Ardeparin decreases the expression of Epidermal growth factor receptor (EGFR).	[39]
Deoxycholic acid	DM3GYAL	Approved	Deoxycholic acid increases the activity of Epidermal growth factor receptor (EGFR).	[41]
Romidepsin	DMT5GNL	Approved	Romidepsin decreases the expression of Epidermal growth factor receptor (EGFR).	[42]
Nevirapine	DM6HX9B	Approved	Nevirapine decreases the expression of Epidermal growth factor receptor (EGFR).	[43]
Lapatinib	DM3BH1Y	Approved	Lapatinib decreases the activity of Epidermal growth factor receptor (EGFR).	[44]
Clofibrate	DMPC1J7	Approved	Clofibrate decreases the expression of Epidermal growth factor receptor (EGFR).	[45]
Vandetanib	DMRICNP	Approved	Vandetanib decreases the activity of Epidermal growth factor receptor (EGFR).	[46]
Lansoprazole	DMXYLQ3	Approved	Lansoprazole increases the expression of Epidermal growth factor receptor (EGFR).	[48]
Osimertinib	DMRJLAT	Approved	Osimertinib decreases the activity of Epidermal growth factor receptor (EGFR).	[49]
Afatinib	DMTKD7Q	Approved	Afatinib decreases the activity of Epidermal growth factor receptor (EGFR).	[50]
Urethane	DM7NSI0	Phase 4	Urethane decreases the expression of Epidermal growth factor receptor (EGFR).	[52]
Dihydrotestosterone	DM3S8XC	Phase 4	Dihydrotestosterone increases the expression of Epidermal growth factor receptor (EGFR).	[53]
Berberine	DMC5Q8X	Phase 4	Berberine decreases the expression of Epidermal growth factor receptor (EGFR).	[54]
Resveratrol	DM3RWXL	Phase 3	Resveratrol decreases the expression of Epidermal growth factor receptor (EGFR).	[55]
Epigallocatechin gallate	DMCGWBJ	Phase 3	Epigallocatechin gallate increases the expression of Epidermal growth factor receptor (EGFR).	[56]
Curcumin	DMQPH29	Phase 3	Curcumin decreases the expression of Epidermal growth factor receptor (EGFR).	[36]
Fenretinide	DMRD5SP	Phase 3	Fenretinide increases the expression of Epidermal growth factor receptor (EGFR).	[57]
Coprexa	DMA0WEK	Phase 3	Coprexa decreases the expression of Epidermal growth factor receptor (EGFR).	[58]
Chloroquine	DMSI5CB	Phase 3 Trial	Chloroquine decreases the expression of Epidermal growth factor receptor (EGFR).	[59]
I3C	DMIGFOR	Phase 3	I3C decreases the expression of Epidermal growth factor receptor (EGFR).	[60]
EXISULIND	DMBY56U	Phase 3	EXISULIND decreases the expression of Epidermal growth factor receptor (EGFR).	[59]
HKI-272	DM6QOVN	Phase 3	HKI-272 decreases the activity of Epidermal growth factor receptor (EGFR).	[50]
CO-1686	DMWZ2TU	Phase 3	CO-1686 decreases the activity of Epidermal growth factor receptor (EGFR).	[49]
Genistein	DM0JETC	Phase 2/3	Genistein decreases the expression of Epidermal growth factor receptor (EGFR).	[61]
Tocopherol	DMBIJZ6	Phase 2	Tocopherol decreases the expression of Epidermal growth factor receptor (EGFR).	[63]
phorbol 12-myristate 13-acetate	DMJWD62	Phase 2	phorbol 12-myristate 13-acetate increases the expression of Epidermal growth factor receptor (EGFR).	[65]
Tanespimycin	DMNLQHK	Phase 2	Tanespimycin decreases the expression of Epidermal growth factor receptor (EGFR).	[66]
NVP-AUY922	DMTYXQF	Phase 2	NVP-AUY922 decreases the expression of Epidermal growth factor receptor (EGFR).	[68]
MK-2206	DMT1OZ6	Phase 2	MK-2206 increases the expression of Epidermal growth factor receptor (EGFR).	[70]
Pelitinib	DMIW453	Phase 2	Pelitinib decreases the activity of Epidermal growth factor receptor (EGFR).	[50]
CI-1033	DMSI8N3	Phase 2	CI-1033 decreases the activity of Epidermal growth factor receptor (EGFR).	[50]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the expression of Epidermal growth factor receptor (EGFR).	[74]
Leflunomide	DMR8ONJ	Phase 1 Trial	Leflunomide increases the expression of Epidermal growth factor receptor (EGFR).	[75]
IRX4204	DM9SCME	Phase 1	IRX4204 decreases the expression of Epidermal growth factor receptor (EGFR).	[78]
TAK-285	DM6KOBZ	Phase 1	TAK-285 decreases the activity of Epidermal growth factor receptor (EGFR).	[79]
PMID28460551-Compound-2	DM4DOUB	Patented	PMID28460551-Compound-2 decreases the expression of Epidermal growth factor receptor (EGFR).	[80]
Flavonoid derivative 1	DMCQP0B	Patented	Flavonoid derivative 1 decreases the expression of Epidermal growth factor receptor (EGFR).	[81]
PMID25656651-Compound-5	DMAI95U	Patented	PMID25656651-Compound-5 decreases the activity of Epidermal growth factor receptor (EGFR).	[82]
Steroid derivative 1	DMB0NVQ	Patented	Steroid derivative 1 decreases the expression of Epidermal growth factor receptor (EGFR).	[22]
P-coumaric acid derivative 6	DMF4YGC	Patented	P-coumaric acid derivative 6 decreases the activity of Epidermal growth factor receptor (EGFR).	[83]
Geldanamycin	DMS7TC5	Discontinued in Phase 2	Geldanamycin decreases the expression of Epidermal growth factor receptor (EGFR).	[85]
PD-153035	DM7KJTI	Discontinued in Phase 1	PD-153035 increases the expression of Epidermal growth factor receptor (EGFR).	[23]
MG-132	DMKA2YS	Preclinical	MG-132 decreases the expression of Epidermal growth factor receptor (EGFR).	[59]
Celastrol	DMWQIJX	Preclinical	Celastrol decreases the expression of Epidermal growth factor receptor (EGFR).	[86]
Ciglitazone	DMAPO0T	Preclinical	Ciglitazone decreases the expression of Epidermal growth factor receptor (EGFR).	[45]

1 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
DNCB	DMDTVYC	Phase 2	DNCB affects the binding of Epidermal growth factor receptor (EGFR).	[64]

References

• [1] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [2] Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
• [3] Epithelial inflammation resulting from an inherited loss-of-function mutation in EGFR. J Invest Dermatol. 2014 Oct;134(10):2570-2578. doi: 10.1038/jid.2014.164. Epub 2014 Apr 1.
• [4] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [5] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [6] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [7] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [8] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [9] Activation of the EGF receptor signaling pathway in human airway epithelial cells exposed to metals. Am J Physiol. 1999 Nov;277(5):L924-31. doi: 10.1152/ajplung.1999.277.5.L924.
• [10] Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother. 2010 Feb;64(2):88-92. doi: 10.1016/j.biopha.2009.06.010. Epub 2009 Oct 23.
• [11] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [12] Influence of Iron on Cytotoxicity and Gene Expression Profiles Induced by Arsenic in HepG2 Cells. Int J Environ Res Public Health. 2019 Nov 14;16(22):4484. doi: 10.3390/ijerph16224484.
• [13] Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct. 2011 Mar;29(2):87-95. doi: 10.1002/cbf.1725. Epub 2011 Feb 9.
• [14] Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp Cell Res. 2010 Aug 1;316(13):2174-88. doi: 10.1016/j.yexcr.2010.04.027. Epub 2010 May 8.
• [15] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [16] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [17] Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells. Pancreas. 2010 Nov;39(8):1277-83. doi: 10.1097/MPA.0b013e3181dd63e1.
• [18] The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009 Feb;41(2):178-186.
• [19] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [20] Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
• [21] Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75. Breast Cancer Res Treat. 2005 Nov;94(2):171-83. doi: 10.1007/s10549-005-7726-6.
• [22] EGF promotes HIF-1 expression in colorectal cancer cells and tumor metastasis by regulating phosphorylation of STAT3. Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1055-1062. doi: 10.26355/eurrev_201902_16993.
• [23] Activation of PPAR and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells. PLoS One. 2020 Aug 21;15(8):e0237976. doi: 10.1371/journal.pone.0237976. eCollection 2020.
• [24] Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance. Anticancer Res. 2008 Mar-Apr;28(2A):895-906.
• [25] Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
• [26] The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol Cell Biochem. 2004 May;260(1-2):129-35. doi: 10.1023/b:mcbi.0000026063.96267.98.
• [27] Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer. 2008 Apr 1;122(7):1645-56. doi: 10.1002/ijc.23280.
• [28] Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway. J Pharmacol Exp Ther. 2004 Jan;308(1):66-72. doi: 10.1124/jpet.103.058321. Epub 2003 Oct 20.
• [29] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [30] Gene expression in human hippocampus from cocaine abusers identifies genes which regulate extracellular matrix remodeling. PLoS One. 2007 Nov 14;2(11):e1187. doi: 10.1371/journal.pone.0001187.
• [31] DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. Mol Cell Biol. 2005 Jun;25(12):5040-51. doi: 10.1128/MCB.25.12.5040-5051.2005.
• [32] A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
• [33] Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway. Oncogene. 2010 Jan 14;29(2):285-96. doi: 10.1038/onc.2009.335. Epub 2009 Oct 26.
• [34] Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
• [35] Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells. Nutr Cancer. 2011;63(7):1133-42. doi: 10.1080/01635581.2011.605984. Epub 2011 Sep 15.
• [36] Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 2015 Dec 5;242:107-22.
• [37] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [38] Cryptotanshinone (Dsh-003) from Salvia miltiorrhiza Bunge inhibits prostaglandin E2-induced survival and invasion effects in HA22T hepatocellular carcinoma cells. Environ Toxicol. 2018 Dec;33(12):1254-1260. doi: 10.1002/tox.22633. Epub 2018 Sep 12.
• [39] Heparin increases human gastric carcinoma cell growth. Anticancer Res. 2006 Jan-Feb;26(1A):439-43.
• [40] Synergistic augmentation of ATP-induced interleukin-6 production by arsenite in HaCaT cells. Arch Toxicol. 2016 Jun;90(6):1307-13. doi: 10.1007/s00204-015-1553-2. Epub 2015 Jun 24.
• [41] Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005 Sep;138(3):415-21. doi: 10.1016/j.surg.2005.06.030.
• [42] Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res. 2004 Mar 1;10(5):1813-25. doi: 10.1158/1078-0432.ccr-0901-3.
• [43] Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
• [44] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [45] Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands. BMC Cancer. 2010 Nov 16;10:629. doi: 10.1186/1471-2407-10-629.
• [46] Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer Sci. 2004 Dec;95(12):984-9. doi: 10.1111/j.1349-7006.2004.tb03187.x.
• [47] Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14555-60.
• [48] Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans. Dig Dis Sci. 1998 Dec;43(12):2764-70. doi: 10.1023/a:1026680017329.
• [49] Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2017 Apr 15;321:18-26. doi: 10.1016/j.taap.2017.02.017. Epub 2017 Feb 22.
• [50] Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J Med Chem. 2011 Mar 10;54(5):1347-55. doi: 10.1021/jm101396q. Epub 2011 Feb 15.
• [51] The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30.
• [52] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [53] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [54] Dual down-regulation of EGFR and ErbB2 by berberine contributes to suppression of migration and invasion of human ovarian cancer cells. Environ Toxicol. 2021 May;36(5):737-747. doi: 10.1002/tox.23076. Epub 2020 Dec 16.
• [55] Resveratrol induces apoptosis and alters gene expression in human fibrosarcoma cells. Anticancer Res. 2015 Feb;35(2):767-74.
• [56] Epigallocatechin-3-gallate (EGCG) protects against chromate-induced toxicity in vitro. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):166-75.
• [57] 4-HPR modulates gene expression in ovarian cells. Int J Cancer. 2006 Sep 1;119(5):1005-13. doi: 10.1002/ijc.21797.
• [58] Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition. Chem Biol Interact. 2023 Sep 1;382:110546. doi: 10.1016/j.cbi.2023.110546. Epub 2023 Jun 7.
• [59] Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor. Cancer Prev Res (Phila). 2010 Apr;3(4):560-72. doi: 10.1158/1940-6207.CAPR-09-0159. Epub 2010 Mar 23.
• [60] Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther. 2007 Nov;6(11):3071-9. doi: 10.1158/1535-7163.MCT-07-0117.
• [61] Genistein-induced changes in gene expression in Panc 1 cells at physiological concentrations of genistein. Pancreas. 2004 Aug;29(2):93-8.
• [62] Cancer metastasis and EGFR signaling is suppressed by amiodarone-induced versican V2. Oncotarget. 2015 Dec 15;6(40):42976-87. doi: 10.18632/oncotarget.5621.
• [63] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [64] Proteomic analysis of the cellular response to a potent sensitiser unveils the dynamics of haptenation in living cells. Toxicology. 2020 Dec 1;445:152603. doi: 10.1016/j.tox.2020.152603. Epub 2020 Sep 28.
• [65] Pterostilbene inhibited tumor invasion via suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. Carcinogenesis. 2009 Jul;30(7):1234-42. doi: 10.1093/carcin/bgp121. Epub 2009 May 15.
• [66] Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. Cells. 2019 Jul 31;8(8):806. doi: 10.3390/cells8080806.
• [67] MiR-3663-3p participates in the anti-hepatocellular carcinoma proliferation activity of baicalein by targeting SH3GL1 and negatively regulating EGFR/ERK/NF-B signaling. Toxicol Appl Pharmacol. 2021 Jun 1;420:115522. doi: 10.1016/j.taap.2021.115522. Epub 2021 Apr 8.
• [68] Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. Cancer. 2013 Jan 15;119(2):293-303. doi: 10.1002/cncr.27743. Epub 2012 Jul 18.
• [69] Comparison of delphinidin, quercetin and (-)-epigallocatechin-3-gallate as inhibitors of the EGFR and the ErbB2 receptor phosphorylation. Mol Nutr Food Res. 2008 Jul;52(7):815-22. doi: 10.1002/mnfr.200800026.
• [70] Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. Sci Rep. 2016 Nov 29;6:37997. doi: 10.1038/srep37997.
• [71] YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells. PLoS One. 2017 Aug 7;12(8):e0182149. doi: 10.1371/journal.pone.0182149. eCollection 2017.
• [72] A nongenomic mechanism for "metalloestrogenic" effects of cadmium in human uterine leiomyoma cells through G protein-coupled estrogen receptor. Arch Toxicol. 2019 Oct;93(10):2773-2785. doi: 10.1007/s00204-019-02544-0. Epub 2019 Aug 29.
• [73] Taurocholate induces cyclooxygenase-2 expression via the sphingosine 1-phosphate receptor 2 in a human cholangiocarcinoma cell line. J Biol Chem. 2015 Dec 25;290(52):30988-1002.
• [74] Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway. Cancer Lett. 2009 Jun 8;278(1):27-33. doi: 10.1016/j.canlet.2008.12.017. Epub 2009 Jan 31.
• [75] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [76] Tetrandrine inhibits human brain glioblastoma multiforme GBM 8401 cancer cell migration and invasion in vitro. Environ Toxicol. 2019 Apr;34(4):364-374. doi: 10.1002/tox.22691. Epub 2018 Dec 13.
• [77] Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid. Int J Oncol. 2005 Sep;27(3):823-30.
• [78] A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res. 2004;6(5):R546-55. doi: 10.1186/bcr913. Epub 2004 Jul 23.
• [79] Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem. 2011 Dec 8;54(23):8030-50. doi: 10.1021/jm2008634. Epub 2011 Nov 4.
• [80] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [81] Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells. Food Chem Toxicol. 2012 Nov;50(11):4136-43. doi: 10.1016/j.fct.2012.08.025. Epub 2012 Aug 20.
• [82] AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.
• [83] Synthesis and characterization of N-coumaroyltyramine as a potent phytochemical which arrests human transformed cells via inhibiting protein tyrosine kinases. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1104-10. doi: 10.1006/bbrc.2002.6752.
• [84] Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J Pharmacol Exp Ther. 2009 Jun;329(3):908-18. doi: 10.1124/jpet.109.152017. Epub 2009 Mar 16.
• [85] Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines. J Pharmacol Exp Ther. 2010 Mar;332(3):949-58. doi: 10.1124/jpet.109.162248. Epub 2009 Dec 9.
• [86] Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006 Oct;10(4):321-30.
• [87] Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFB and AhR and EGFR-ERK pathway. Toxicol Appl Pharmacol. 2011 Sep 1;255(2):138-49.
• [88] Epidermal growth factor receptor transactivation by the cannabinoid receptor (CB1) and transient receptor potential vanilloid 1 (TRPV1) induces differential responses in corneal epithelial cells. Exp Eye Res. 2010 Sep;91(3):462-71. doi: 10.1016/j.exer.2010.06.022. Epub 2010 Jul 7.
• [89] Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology. 2007;73(1-2):104-11. doi: 10.1159/000120998. Epub 2008 Mar 13.
• [90] Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma. Cancer Lett. 2009 Jun 28;279(1):30-8. doi: 10.1016/j.canlet.2009.01.019. Epub 2009 Feb 12.
• [91] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [92] EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Arch Toxicol. 2015 Apr;89(4):591-605. doi: 10.1007/s00204-014-1275-x. Epub 2014 Jun 3.
• [93] The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12932-7. doi: 10.1073/pnas.0906606106. Epub 2009 Jul 22.
• [94] Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10.
• [95] Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.
• [96] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [97] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
• [98] Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res Treat. 2009 Mar;114(1):23-30. doi: 10.1007/s10549-008-9969-5. Epub 2008 Mar 21.
• [99] Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res. 2012 Dec 15;18(24):6771-83. doi: 10.1158/1078-0432.CCR-12-2347. Epub 2012 Nov 7.
• [100] A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011 Sep 15;71(18):6051-60. doi: 10.1158/0008-5472.CAN-11-1340. Epub 2011 Jul 26.